November 2, 2016 Drug & Device Advisory Group FDA Briefs FDA Facts: Abuse-Deterrent Opioid Medications WHAT: FDA Website on FDA standards for Abuse-Deterrent (AD) opioid formulations WHY: To help drug makers expedite regulatory path to market as quickly as possible. FDA is taking a flexible, adaptive approach to the evaluation and labeling of potentially AD products. WHICH: …
March 3, 2020 Drug & Device Advisory Group Link and Learn Increased availability of NIOSH approved respirators to healthcare personnel FDA and CDC take action to increase access to respirators, including N95s, for health care personnel FDA-CDC collaboration to prioritize access to needed medical products through Emergency Use Authorization (EUA) Certain industrial respirators during the …
Increased availability of NIOSH approved respirators to healthcare personnel Read More »
